MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Home・Akcijų sąrašas・Denali Therapeutics Inc

Denali Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

19.36 -5.84

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.16

Max

20.56

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -129M
Darbuotojai	503
EBITDA	8.9M -125M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+74.33% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-390M 2.9B
Ankstesnė atidarymo kaina	25.2
Ankstesnė uždarymo kaina	19.36

Naujienos nuotaikos

By Acuity

18%

82%

50 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

13.355 / 16.44 Palaikymas ir pasipriešinimas

Denali Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-06 23:17; UTC

Uždarbis

Samsung Forecasts Record First-Quarter Operating Profit

2026-04-06 23:00; UTC

Karštos akcijos

Stocks to Watch: Health Insurers, Mawson, Owlet

2026-04-06 22:13; UTC

Pagrindinės rinkos jėgos

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026-04-06 21:46; UTC

Įsigijimai, susijungimai, perėmimai

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026-04-06 17:09; UTC

Pagrindinės rinkos jėgos

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026-04-06 16:56; UTC

Svarbiausios naujienos

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026-04-06 14:47; UTC

Pagrindinės rinkos jėgos

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026-04-07 00:00; UTC

Svarbiausios naujienos

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026-04-06 23:58; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026-04-06 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026-04-06 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026-04-06 23:15; UTC

Rinkos pokalbiai

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026-04-06 22:14; UTC

Rinkos pokalbiai

Correction to Live Cattle Futures Article

2026-04-06 20:56; UTC

Rinkos pokalbiai

Mexican Private Consumption Fell in January -- Market Talk

2026-04-06 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-06 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026-04-06 19:11; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026-04-06 19:06; UTC

Rinkos pokalbiai

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026-04-06 18:36; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 17:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026-04-06 17:13; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 16:33; UTC

Rinkos pokalbiai

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026-04-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-06 14:59; UTC

Uždarbis

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Akcijų palyginimas

Kainos pokytis

Denali Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

74.33% į viršų

12 mėnesių prognozė

Vidutinis 36 USD 74.33%

Aukščiausias 42 USD

Žemiausias 30 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Denali Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių Denali Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

13.355 / 16.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Rinkos nuotaikos

By Acuity

50 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.